NCT04459598View on ClinicalTrials.gov

A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 19, 2020

Primary Completion Date

October 14, 2020

Study Completion Date

October 14, 2020

Conditions
Healthy SubjectsDrug-drug InteractionPharmacokineticsQuizartinib
Interventions
DRUG

Efavirenz

Single oral dose, 600-mg tablet

DRUG

Quizartinib

Single oral dose, 60 mg (2 x 30 mg) tablets

Trial Locations (1)

78217

Worldwide Clinical Trials, San Antonio

Sponsors
All Listed Sponsors
lead

Daiichi Sankyo Co., Ltd.

INDUSTRY

NCT04459598 - A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants | Biotech Hunter | Biotech Hunter